Cited by 600Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancerPARP inhibition in cancer therapy

The DOI matches its Crossref record; 55 of the 58 references it cites were found in a registry or an index.

Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

Open access

Perets, Ruth, Wyant, Gregory A., Muto, Katherine W., Bijron, Jonathan G., Poole, Barish B., Chin, Kenneth T., Chen, Jin Yun H., Ohman, Anders W., Stepule, Corey D., Kwak, Soongu, Karst, Alison M., Hirsch, Michelle S., Setlur, Sunita R., Crum, Christopher P., Dinulescu, Daniela M., Drapkin, Ronny·2013·Cancer Cell

DOI 10.1016/j.ccr.2013.10.013PMC PMC3917315

Open this paper in CoChat — free account Open PDF

Abstract

High-grade serous ovarian carcinoma presents significant clinical and therapeutic challenges. Although the traditional model of carcinogenesis has focused on the ovary as a tumor initiation site, recent studies suggest that there may be additional sites of origin outside the ovary, namely the secretory cells of the fallopian tube. Our study demonstrates that high-grade serous tumors can originate in fallopian tubal secretory epithelial cells and also establishes serous tubal intraepithelial carcinoma as the precursor lesion to high-grade serous ovarian and peritoneal carcinomas in animal models targeting the Brca, Tp53, and Pten genes. These findings offer an avenue to address clinically important questions that are critical for cancer prevention and early detection in women carrying BRCA1 and BRCA2 mutations.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2013.10.013

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Generalized lacZ expression with the ROSA26 Cre reporter strain
Soriano, P. (1999) · Nature Genetics · doi:10.1038/5007 · Cited by 5,237
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,484
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,204
Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C. M., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,114

Show all 58 references

Sorted by citations

Items 501–600 of 600

Somatic chromosomal number alterations affecting driver genes inform in-vitro and clinical drug response in high-grade serous ovarian cancerPreprint
Martins, F. C., Couturier, D., de Santiago, I., Sauer, C. M., Vias, M., Angelova, M., Sanders, D. A., Piskorz, A., Hall, J. A. M., Hosking, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.10.04.325365 · Cited by 1
Down-regulation of protein phosphatases PPM1K and PPP1R3C in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/ps6fq · Cited by 1
Female Reproductive System
Dixon, D., Nikitin, A. Y., & Mahler, J. F. (2021) · doi:10.1002/9781119624608.ch19 · Cited by 1
ASPM is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/erdfb · Cited by 1
FGF10 is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/ba2jg · Cited by 1
Combinatorial organoid mutagenesis screen reveals gene constellations driving malignant transformation, pathology and chemosensitivity in high-grade serous ovarian carcinomaPreprint
Phuong, D. J., Ralston, C. Q., Ezzat, T., Ashe, C. S., Armstrong, A. P., Flesken‐Nikitin, A., Yamulla, R. J., Nikitin, A. Y., & Schimenti, J. C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.10.642422 · Cited by 1
Tumor Microenvironment in Ovarian Cancer through Spatial Transcriptomics and Identification of Key Gene Expression ProfilesPreprint
Kırboğa, K. K., Küçüksille, E. U., Rudrapal, M., Aktaş, E., Achar, R. R., Deshpande, G., Stupin, V. A., & Silina, E. V. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.25.650590 · Cited by 1
Single cell functional immunogenomics of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer preventionPreprint
Wang, L., Roskams-Hieter, B., Hussain, N., Nulsen, J., Aggarwal, A., Sallam, M., Wang, L., Rai, L. J., Ahmed-Ebbiary, A., Al-Deka, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.30.662408 · Cited by 1
Analiza molekularna kompleksu genów MRE11/RAD50/NBS1 w rodzinach z agregacją zachorowań na raki piersi i/lub jajnika
Antoszewska, E. (2021) · doi:10.48745/ppm.5hvx-b085
A better mimic
Seton-Rogers, S. E. (2014) · Nature reviews. Cancer · doi:10.1038/nrc3674
Evolving Models of Ovarian Cancer: Defining the Role of PAX8 in Fallopian Tube Tumorigenesis
Emori, M. M. (2015) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Precursors of Low-Grade Serous Adenocarcinoma of the Ovary: Pathology and Molecular Pathways
Lawrenson, K., & Mhawech-Fauceglia, P. Y. (2015) · Springer eBooks · doi:10.1007/978-3-319-22509-8_2
Impact of the ovarian microenvironment on serous cancer
Burdette, J. E. (2016)
Cyclin E1 as a therapeutic target in high grade serous ovarian cancer
Au‐Yeung, G. (2017) · Minerva Access (University of Melbourne)
Molecular Mechanisms of Therapeutic Resistance in Cancer.
Wang, H. (2014) · Deep Blue (University of Michigan)
Ovarian Cancer Genome and Molecular Experimental Sciences
Matsumura, N., & Konishi, I. (2017) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-10-4160-0_7
Assessment Of A Function For Threonyl-Trna Synthetase In Angiogenesis In A Mouse Ovarian Cancer Model
Wo, P. (2017) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont)
Role of Lgr5-Expressing Stem Cells in Epithelial Renewal and Cancer in the Reproductive Tract
Ng, A., & Barker, N. (2018) · Springer eBooks · doi:10.1007/978-981-10-7941-2_4
High-grade Pelvic Serous Carcinoma Within the Fallopian Tube Lumen: Real or Artifact?
Seidman, J. D., & Krishnan, J. (2019) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000649
Development of molecular inhibitor nanoformulations for cancer therapy
Baldwin, P. (2019) · Digital Repository Service (Northeastern University) · doi:10.17760/d20317945
Ovarian serous carcinoma: A retrospective study of clinicopathological findings and postchemotherapy changes
Vangala, N., Uppin, S. G., Uppin, M. S., Paul, T. R., & Sadashivudu, G. (2020) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_199_19
Epithelial ovarian cancer: Genomic landscape and evolving precision treatment
DeFazio, A., Gao, B., Mapagu, C., Moujaber, T., & Harnett, P. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00007-8
Models of ovarian cancer to test new agents
Sodi, V. L., Craig, A. D., Peri, S., & Connolly, D. C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00012-1
Investigating the Molecular Carcinogenesis of Ovarian High-Grade Serous Carcinoma
Kyo, S. (2021) · Current human cell research and applications · doi:10.1007/978-981-33-6013-6_4
Molecular Characterization of Mouse Models of High Grade Serous Carcinoma Based on Oviductal Epithelial Transformation
Schulman, S. (2018) · Deep Blue (University of Michigan)
Comparative characteristics of models of advanced ovarian carcinoma after orthotopic and intraperitoneal transplantation of a syngeneic tumor
Murazov, Y. G., Стуков, А. Н., Нюганен, А. О., & Artem`eva, A. (2021) · Voprosy Onkologii · doi:10.37469/0507-3758-2021-67-2-300-308
Reportage: ‘Broeders’ van Jetse Batelaan op de Wiener Festwochen
van den Berg, S. (2008)
Block Copolymer Nano-Structured Materials
Fryd, M., & Wayland, B. B. (2007) · ScholarlyCommons (University of Pennsylvania)
Faculty Opinions recommendation of Most Commonly Mutated Genes in High-Grade Serous Ovarian Carcinoma Are Nonessential for Ovarian Surface Epithelial Stem Cell Transformation.
Chen, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738598679.793578219
Transplantation Into the Mouse Ovarian Fat Pad
Flesken‐Nikitin, A., Harlan, B. A., & Nikitin, A. Y. (2016) · Journal of Visualized Experiments · doi:10.3791/54444-v
Thyrotroph embryonic factor (TEF) is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/djec5
Quantitative clonal analysis reveals vast heterogeneity among fallopian tube cells for ovarian cancer-initiation and progressionPreprint
Zeng, J., Álvarez-Yela, A. C., Casarez, E. V., Jiang, Y., Wang, L., Kelly, B. E., Ke, E., Jenkins, T. M., Atkins, K. A., Janes, K. A., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.23.477434
Epithelial Tumors of the Ovary
Seidman, J. D., Ronnett, B. M., Shih, I., Cho, K. R., & Kurman, R. J. (2018) · Springer eBooks · doi:10.1007/978-1-4614-3165-7_14-3
FBXO30 is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/8yztx
The progesterone receptor is differentially expressed in epithelial ovarian cancer and its expression correlates with patient survival.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/v976x
STARD9 is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/w4hj3
Multiple members of the transcription factor elongation A like (TCEAL) family are differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/m9fsw
The transcription elongation factor A like 7 (TCEAL7) is differentially expressed in high-grade serous ovarian cancers and its expression associates with patient survival.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/k6v47
ESPL1 (Separase) is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/zymh9
TPX2 is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/vnquh
MIR503HG is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/5euqy
C2 is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/b3t6n
Frizzled class 7 receptor is differentially expressed in high-grade serous ovarian cancer and based on patient survival.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/aqzj9
Thyroid hormone receptor (TRα) / NR1A1 is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/nkva7
DUSP26 is differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/sp7eh
Over-expression of the kayopherin 𝛂2 gene (KPNA2) in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/57sab
Faculty Opinions recommendation of Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma.
Drapkin, R., & Knarr, M. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736988471.793573757
Sense and anti-sense transcripts at the PGM5 locus are differentially expressed in high-grade serous ovarian cancers.Preprint
Mamoor, S. (2020) · doi:10.31219/osf.io/9xrgp
Tuneable 3D biocompatible scaffolds for biological and biophysical solid-tumour microenvironment studies; applications in Ovarian Cancer
Paradiso, F. (2022) · Cronfa (Swansea University) · doi:10.23889/suthesis.60122
Theories regarding the origin and carcinogenesis of high-grade epithelial ovarian carcinoma and their clinical implications
Staicu, A., Tőkés, R.-E., Goidescu, I. G., Florian, A. R., Cruciat, G., & Mureșan, D. (2022) · Obstetrica şi Ginecologia · doi:10.26416/obsgin.70.3.2022.7200
Unravelling the role of signal transduction pathways in high-grade serous carcinogenesis
van der Ploeg, P. (2023) · doi:10.26481/dis.20230113pp
Animal Models of Gynecological Cancers
Venkata, P. P., Medina, D., Nirzhor, S. S. R., Sittadjody, S., Kumaran, R., Ramachandran, I., & Subbarayalu, P. (2023) · Handbook of Animal Models and its Uses in Cancer Research · doi:10.1007/978-981-19-3824-5_18
Data from The miR–181a–SFRP4 Axis Regulates Wnt Activation to Drive Stemness and Platinum Resistance in Ovarian Cancer
Nagaraj, A. B., Knarr, M., Sekhar, S. C., Connor, R. S., Joseph, P. L., Kovalenko, O., Fleming, A., Surti, A., Nurmemmedov, E., Beltrame, L., et al. (2023) · doi:10.1158/0008-5472.c.6512913.v1
Data from Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis
Wang, Y., Zhao, G., Condello, S., Huang, H., Cárdenas, H., Tanner, E. J., Wei, J., Ji, Y., Li, J., Tan, Y., et al. (2023) · doi:10.1158/0008-5472.c.6512649.v1
Data from Unraveling the Mysteries of PAX8 in Reproductive Tract Cancers
Chaves‐Moreira, D., Morin, P. J., & Drapkin, R. (2023) · doi:10.1158/0008-5472.c.6512509.v1
Data from Chemotherapy Induces Tumor-Associated Macrophages that Aid Adaptive Immune Responses in Ovarian Cancer
Heath, O. M., Berlato, C., Maniati, E., Lakhani, A., Pegrum, C., Kotantaki, P., Elorbany, S., Böhm, S., Barry, S. T., Annibaldi, A., et al. (2023) · doi:10.1158/2326-6066.c.6550176
Data from Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E. P., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2023) · doi:10.1158/2159-8290.c.6548069
Engineering Approaches in Ovarian Cancer Cell Culture
Iwanicki, M., Pavlovič, T., & Behboodi, P. (2023) · Current cancer research · doi:10.1007/978-3-031-22802-5_8
Identifying Novel Candidate Biomarkers of Early Epithelial Ovarian Cancer
Sczelecki, S. (2023) · doi:10.26686/wgtn.22729361
Heme oxygenase-1 expressing omental macrophages as a therapeutic target in ovarian high grade serous carcinomaPreprint
Spear, S., Saux, O. L., Mirza, H., Tyson, K., Bickel, J. K., Freile, F. G., Siskos, A., Balcells, C. D., Walton, J. B., Woodman, C. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.18.549474
Cancer risk in polycystic ovary syndrome patients: Common treatments and future perspectives
Shahrin, A., Mele, M. A., & Islam, M. K. (2023) · Journal of Multidisciplinary Sciences · doi:10.33888/jms.2023 · Cited by 1
The Molecular Classification of Ovarian Cancer and Implication for Treatment
Kossaï, M., Cavaillé, M., & Penault-Llorca, F. M. (2023) · Essentials of Diagnostic Gynecological Pathology. · doi:10.1007/978-3-031-39659-5_13
Loss of phosphatase and tensin homolog (PTEN) increases Lysyl oxidase-like 2 (LOXL2) expression enhancing the growth of fallopian tube epithelial cells as three-dimensional spheroids
Russo, A., Moy, J., Khin, M., Dorsey, T. R., Carrero, A. L., & Burdette, J. E. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.03.003
Additional file 4 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Yu, X., Lin, W., Spirtos, A. N., Wang, Y., Chen, H., Ye, J., Parker, J. E., Liu, C. C., Wang, Y., Quinn, G. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21069666
Additional file 6 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Yu, X., Lin, W., Spirtos, A. N., Wang, Y., Chen, H., Ye, J., Parker, J. E., Liu, C. C., Wang, Y., Quinn, G. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21069672
Additional file 5 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Yu, X., Lin, W., Spirtos, A. N., Wang, Y., Chen, H., Ye, J., Parker, J. E., Liu, C. C., Wang, Y., Quinn, G. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21069669
Additional file 3 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Yu, X., Lin, W., Spirtos, A. N., Wang, Y., Chen, H., Ye, J., Parker, J. E., Liu, C. C., Wang, Y., Quinn, G. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21069663
Additional file 2 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Yu, X., Lin, W., Spirtos, A. N., Wang, Y., Chen, H., Ye, J., Parker, J. E., Liu, C. C., Wang, Y., Quinn, G. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21069660
Ovarian Epithelial Carcinogenesis
Liu, J. (2024) · Springer eBooks · doi:10.1007/978-981-19-7696-4_4-1
Stromal mediated DNA damage promotes high grade serous ovarian cancer initiationPreprint
Garcia, G. L., Orellana, T. J., Gorecki, G., Frisbie, L. G., Baruwal, R., Goldfield, E., Beddows, I., MacFawn, I., Britt, A. K., Hale, M. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.23.595550
ULK1 is required for autophagy and promotes metastatic progression in epithelial ovarian cancerPreprint
Shepherd, T. G., Webb, J., Buensuceso, A. V., Tomas, E. J., Borrelli, M. J., Viola, L., Hovey, O. F. J., Valdés, Y. R., Singha, B., & Li, S. S. ‐. (2024) · Research Square · doi:10.21203/rs.3.rs-5153449/v1
Ovarian carcinomas: clinicopathological and molecular characteristics. Comments on the 2014 FIGO staging system
Prat, J., D′Angelo, E., & Espinosa, Í. (2024) · Revisiones en cáncer · doi:10.20960/revcancer.00082
The relationship between HYDIN and fallopian tubal cilia loss in patients with epithelial ovarian cancer
Guo, Y., He, X., Liu, J., Tan, Y., Zhang, C., Chen, S., & Zhang, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1495753
Uterine Tumors and the Environment
Yang, S., Parra-Forero, L. Y., Andrus, A. R., Sexton, C. N., Kuang, D., & Nowak, R. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00256-4
Ovarian Epithelial Carcinogenesis
Liu, J. (2025) · Springer eBooks · doi:10.1007/978-981-97-4822-8_4
scRNA-seq Can Identify Different Cell Populations in Ovarian Cancer Bulk RNA-seq Experiments
Gabrilovich, S., Devor, E. J., Cardillo, N., Bender, D., Goodheart, M. J., & Bosquet, J. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157512
Redefining Risk, Biomarkers, and Precision Therapy for Hereditary Ovarian Cancer: A Review
Jha, A. N., Gaikwad, V. R., Gupta, A. K., Mulla, T., Drashti, D., Dodiya, R., & Singh, S. K. (2025) · ACS Omega · doi:10.1021/acsomega.5c05260
Surface proteomics reveals arginine metabolism as a vulnerability in high grade serous ovarian cancerPreprint
Govindarajan, M., Waas, M., Meija-Guerrero, S., Lin, B., Ling, T., Li, X., Ignatchenko, V., Tikhonova, A. N., Jones, C. L., Ailles, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.02.673726
A Rare Multipotent Peg-like Epithelial Cell is a Candidate Cell-of-Origin for High-Grade Serous Ovarian CancerPreprint
Ritting, M. L., Yang, W., Aalam, S. M. M., Zhao, H., Liang, F., Song, J., Dumbrava, M. G., Ismail, W. M., Mun, D., Hu, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.09.23.677404
Development and Application of MiMouse, a Comprehensive Genomic Profiling Panel for Credentialing Mouse Tumor Models
Hu, K., Liu, C.-J., Qin, Z., Udager, A. M., Cieslik, M. P., & Tomlins, S. A. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0279
Targeting ALC1 can safely expand the therapeutic utility of PARP inhibitors across high-grade serous ovarian cancersPreprint
Aubuchon, L. N., Wong, D. H., Ramakrishnan, N., Greenberg, S. F., Reddy, R., Lomonosova, E., Compadre, A. J., Jackson, K. E., Kemper, D., Mehta, V. V., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.04.692458
Aktuelle Aspekte zur Tumorigenese und Ätiologie
Darb‐Esfahani, S., Denkert, C., & Dietel, M. (2014) · Der Onkologe · doi:10.1007/s00761-014-2682-6
Additional file 1 of A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer
Lo Riso, P., Villa, C. E., Gasparoni, G., Vingiani, A., Luongo, R., Manfredi, A., Jungmann, A., Bertolotti, A., Borgo, F., Garbi, A., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13167189
Additional file 1 of Dissection of transcriptome dysregulation and immune characterization in women with germline BRCA1 mutation at single-cell resolution
Yu, X., Lin, W., Spirtos, A. N., Wang, Y., Chen, H., Ye, J., Parker, J. E., Liu, C. C., Wang, Y., Quinn, G. M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21069657
Additional file 1 of ARID1A loss activates MAPK signaling via DUSP4 downregulation
Mandal, J., Yu, Z.-C., Shih, I., & Wang, T. (2024) · Figshare · doi:10.6084/m9.figshare.26651652
EPI-SauriCas9-based mouse ovarian cancer models recapitulating pten deletion in patients
Chen, W., He, P., Ding, L., Lou, W., Wang, Y., Shi, W., Fan, Z., Sheng, Y., Luo, J., Tan, Z., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-09437-2 · Cited by 1
Stromal estrogen signaling regulates fallopian tube homeostasis and cancer initiation via inflammatory pathwaysPreprint
Chen, X., Han, S., Zhao, D., Qin, G. T., & Li, Z. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.21.700864
Comparative single-cell atlases reveal injury-driven tubal epithelial regeneration as a window for ovarian carcinoma initiationPreprint
Ralston, C. Q., Flesken‐Nikitin, A., Fu, D., Ashe, C. S., Harlan, B. A., Hossain, M. M., Wang, D. Y., Yemelyanova, A. V., Schmoeckel, E., Godwin, A. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.26.714557
Multiplex organoid mutagenesis reveals gene combinations driving transformation, pathology, and chemosensitivity in ovarian carcinoma
Phuong, D. J., Ralston, C. Q., Ezzat, T., Ashe, C. S., Armstrong, A. P., Flesken‐Nikitin, A., Yamulla, R. J., Nikitin, A. Y., & Schimenti, J. C. (2026) · Genetics · doi:10.1093/genetics/iyag098 · Cited by 2
CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7 ‐ H3
Saleh, A., Medina‐Itzhaki, N., Chekov, M., Gal‐Swisa, E., Gabesh‐Wahabi, R., Savyon, I., Naroditsky, I., Kenny, H. A., Fares, B., Korsensky, L., et al. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70235
RBX1 loss sensitizes tubo-ovarian, high-grade serous ovarian cells to CDK2 inhibition by SNS-032
Farrell, A. C., Lam, L. A., Chen, H., Neudorf, N. M., Sajesh, B. V., Lepage, C. C., Lichtensztejn, Z., & McManus, K. J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1781550
Untangling the Labyrinth: An Integrated View of the Mesothelial and Epithelial Linings of the Female Adnexa Based on Newly Characterized Anatomic and Histologic Junctions
Seidman, J. D., & VANG, R. S. (2026) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000001167
Transcriptomic analysis of tissue-resident memory T cells of the fallopian tube reveals a precursor immune surveillance network for ovarian cancer prevention
Wang, L., Roskams-Hieter, B., Hussain, N., Nulsen, J., Aggarwal, A., Sallam, M., Wang, L., Rai, L. J., Shi, H., Ahmed-Ebbiary, A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74599-4 · Cited by 1
Models of high-grade serous carcinoma of tubo-ovarian origin
Padmanabhan, A., Dwivedi, S. K. D., Merritt, M. A., Verma, P., Buckanovich, R. J., Lang, J. D., Dimmick, H. L., Nephew, K. P., Drapkin, R., Brubaker, L. W., et al. (2026) · Oncology Reviews · doi:10.3389/or.2026.1849834
Single-cell mapping of the fallopian tube reveals a genomically unstable secretory cell state enriched in carriers of germline BRCA1/2 mutationsPreprint
Eyal-Lubling, Y., Vias, M., Kania, K., Kaludova, D., Hall, J., Crawford, R., Nyagumbo, R., Ward, S., Khoronenkova, S., Aparicio, S. A. J. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.26.746998 · Cited by 1
Folate Receptor Alpha Expression Across the Spectrum of Serous Tubal Lesions
Feng, Y., Fan, R., Yao, Z., Yuan, Z., Zhao, R., Liu, Y., Quddus, M. R., Fadare, O., Lea, J. S., Kong, B., et al. (2026) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002612
Ovarian Precancerous Lesions and Their Molecular Landscape: A Structured Scoping Review Focused on STIC and Related Precursors of Epithelial Ovarian Cancer
Kwas, K., Lisińska, W., Koziróg, E., Stanek, K., Wolder, D. P., Szubert, M., & Wilczyński, J. R. (2026) · Cancers · doi:10.3390/cancers18183036
A fluidic-shear device for minimally disruptive, site-selective collection of viable cells from excised fallopian-tube tissue
Avalle, D., Vandereydt, B., Parks, S. M., Peng, H., Stone, R., Belcher, A. M., & Varanasi, K. K. (2026) · Device · doi:10.1016/j.device.2026.101305
Standardizing Cell Ontology terms for cross-study integration in the female reproductive tract
Ong, H. T., Saunders, D. C., Eastwood, C., Puig-Barbe, A., Kochersberger, A., Galligos, A. M., Marshall, B., Johnson, B. K., Kratka, C. E., Jin, C., et al. (2026) · Science Advances · doi:10.1126/sciadv.aef2358
Endogenous replication stress creates a unique therapeutic window for ALC1 targeting
Aubuchon, L. N., Wong, D. H., Greenberg, S., Jackson, K. E., Reddy, R., Lomonosova, E., Compadre, A. J., Kemper, D., Mehta, V., Zoberi, K., et al. (2026) · EMBO Reports · doi:10.1038/s44319-026-00966-3

Authors: Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., Karst, A. M., Hirsch, M. S., Setlur, S. R., Crum, C. P., Dinulescu, D. M., & Drapkin, R.
Affiliations: Harvard University (US)
Brigham and Women's Hospital (US)
Corresponding author: Dinulescu, Daniela M.
Drapkin, Ronny
ORCID: Perets, Ruth
Wyant, Gregory A.
Hirsch, Michelle S.
Setlur, Sunita R.
Crum, Christopher P.
Dinulescu, Daniela M.
Drapkin, Ronny
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2013-12
Volume: 24
Issue: 6
Pages: 751-765
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2013.10.013
PMC: PMC3917315
OpenAlex: W2013107316
Cited by: 596
References: 58
Citations by year: 2026: 23 · 2025: 49 · 2024: 35 · 2023: 47 · 2022: 47 · 2021: 46 · 2020: 85 · 2019: 44 · 2018: 42 · 2017: 44 · 2016: 51 · 2015: 49 · 2014: 32
FWCI: 52.89
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 373 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Wellcome Trust
National Institutes of Health
National Cancer Institute (R21CA156021, U01CA152990, P50CA105009)
Topics: Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Keywords: high-grade serous ovarian cancer, serous tubal intraepithelial carcinoma, cancer of unknown primary, BRCA1, BRCA2, TP53, PTEN, peritoneal cancer, precursor lesions, cancer prevention, early detection
MeSH terms: PAX8 Transcription Factor, Animals, Cell Transformation, Neoplastic, Epithelium, Fallopian Tube Neoplasms, Female, Mice, Inbred C57BL, Ovarian Neoplasms, Precancerous Conditions, Genes, p53, Cystadenocarcinoma, Serous, Genes, BRCA1, Integrases, Genes, BRCA2, PTEN Phosphohydrolase, Mice, Paired Box Transcription Factors, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Transformation of the Fallopian Tube Secretory Epithelium Leads to High-Grade Serous Ovarian Cancer in Brca;Tp53;Pten Models

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks